The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
Pfizer is a large pharmaceutical company founded in 1849. In 2014, Pfizer's revenue was $53.8 billion with net income of $22 billion. Pfizer's top selling drugs include Lipitor, Lyrica, and Viagra. The company is evaluating strategic options to maintain its leadership position, including horizontal integration through an acquisition of AstraZeneca. In May 2014, Pfizer offered $117 billion for AstraZeneca, but the offer was rejected. Pfizer will likely need to make another major acquisition in the next 4-5 years to continue growing and remain the largest pharmaceutical company.
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
Pfizer is a large pharmaceutical company founded in 1849. In 2014, Pfizer's revenue was $53.8 billion with net income of $22 billion. Pfizer's top selling drugs include Lipitor, Lyrica, and Viagra. The company is evaluating strategic options to maintain its leadership position, including horizontal integration through an acquisition of AstraZeneca. In May 2014, Pfizer offered $117 billion for AstraZeneca, but the offer was rejected. Pfizer will likely need to make another major acquisition in the next 4-5 years to continue growing and remain the largest pharmaceutical company.
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Pfizer Inc. is the world's largest pharmaceutical company with global operations in over 79 locations. The company applies science and resources to develop therapies that improve lives. Pfizer divides its business into innovative pharmaceuticals, vaccines and consumer healthcare. Key products include Prevnar/Prevenar 13, Lyrica, and Viagra. While facing competition from generic drugs and facing high barriers to entry, Pfizer maintains a leading market position through a diverse portfolio and strong brand recognition.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of Pfizer's financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
Pfizer is a large pharmaceutical company founded in 1849 and headquartered in New York. It has annual sales of $44.4 billion and focuses on areas like cardiovascular, infectious diseases, and oncology. While Pfizer has significant market share and resources, it also faces threats such as expiring patents, increased competition from generics, and a reliance on blockbuster drugs.
Pharmaceutical industry pestel analysisRahul Pagaria
The pharmaceutical industry in India is a rapidly growing sector that produces low-cost, high-quality drugs. It has a total market size of over $20 billion and has grown at around 12.5% annually over the past five years. Key players in the industry include Ranbaxy, Dr. Reddy's, Cipla, and Lupin. A PESTEL analysis identified political issues like price controls, social factors like an aging population and increased patient expectations, economic challenges from the global crisis, opportunities from new technologies, and an increasing focus on the environmental impact of the industry.
Strategic Management project on Johnson & Johnson Shobhita Dayal
This presentation talks about the complete framework of the strategic planning of the Johnson & Johnson company. All the topics of strategic management course is been covered, in this ppt starting from SWOT, Strategic Map, External Factor Analysis, and all other major strategic tools.
This document provides a business report on Pfizer Inc. prepared by Aileen Marshall. It includes an executive summary analyzing Pfizer's position in the pharmaceutical market. It then gives a company snapshot of Pfizer, including key facts, products, acquisitions and financial performance. Finally, it begins an analysis of Pfizer's current position using a PEST analysis and SWOT analysis to examine political, economic, social, technical, strengths, weaknesses, opportunities and threats facing the company.
Competitive advantage and strategy formulation processvitusmaren
This document discusses the competitive advantages and strategy formulation processes of three large pharmaceutical companies: Novartis, Pfizer, and Sanofi-Aventis. It outlines how Novartis was formed through a merger and leads in various therapeutic areas. Pfizer invests heavily in research and develops blockbuster drugs. Sanofi-Aventis has a large diversified drug portfolio and global vaccine leadership. The strategy formulation process for Novartis is also summarized, including its mission to discover and market innovative products, objectives like eliminating diseases, and potential strategies like investing in R&D.
The document discusses how various factors in the PESTEL analysis impact the pharmaceutical industry in India. It outlines how the political, economic, sociological, technological, ecological, and legal environments can positively or negatively influence the industry. A stable government, growing economy, educated society, advancing technology, balanced environment, and supportive laws create opportunities for pharmaceutical companies to develop and thrive.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
Abbott Laboratories (Pakistan) is a pharmaceutical company founded in 1888 that has been operating in Pakistan since 1948. It has over 1,500 employees and manufacturing facilities in Karachi. The company produces pharmaceuticals, nutritional products, diagnostics, and medical devices. Abbott's main competitors in Pakistan include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, and Pfizer. An analysis of Abbott's strengths, weaknesses, opportunities, and threats was conducted, as well as financial analysis showing steady growth from 2012-2017. Recommendations included focusing on products with fewer side effects, reducing employee turnover, engaging with the government, and adopting new technologies.
Johnson & Johnson is a global healthcare company headquartered in New Jersey. It has over 110,000 employees worldwide and sells products in over 175 countries. In 2011, it achieved $65 billion in sales. The company focuses on consumer health, pharmaceuticals, and medical devices/diagnostics. It aims to provide high-quality products and services to improve health and quality of life. Johnson & Johnson faces competition from companies like Abbott Laboratories, Merck, Novartis, and Pfizer but maintains strength through its diverse product portfolio and strong brand loyalty.
Pfizer is the world's largest pharmaceutical company with revenues of $49.6 billion in 2014. It has over 78,000 employees worldwide and key products include Lipitor, Lyrica, Viagra, and Celebrex. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. Pfizer utilizes a complex global supply chain network involving over 300 suppliers to procure and deliver materials and finished products to customers in over 175 distribution centers worldwide while managing risks such as cargo theft and counterfeiting.
This document provides an analysis of Johnson & Johnson, a global healthcare company. It begins with an overview of the company's history and operations, including its founding in 1886 and presence in over 60 countries. It then analyzes Johnson & Johnson's business segments, competitors, mergers and acquisitions, sales, value chain, and SWOT profile. The document also performs a PEST analysis and recommends how Johnson & Johnson can improve its response to quality control issues to restore its reputation. In summary, the document analyzes Johnson & Johnson's global business environment through an examination of its operations, strategy, and external factors.
Peloton Interactive Analysis by Berkley McFarlinBerkleyMcFarlin
This document provides a comprehensive analysis of Peloton Interactive, Inc. It begins with a financial analysis noting Peloton's high revenues compared to competitors but consistent net losses. An external analysis uses Porter's Five Forces model to examine Peloton's competitive environment and identifies opportunities and threats. An internal analysis evaluates Peloton's value chain and strengths and weaknesses. The document concludes with recommendations for Peloton to respond to COVID-19, optimize competitive opportunities, and increase its stock price.
- The document analyzes the five forces model, PESTLE analysis, and SWOT analysis for a pharmaceutical company.
- It identifies strong competition from generic drugs, high R&D costs, and stringent FDA regulations as challenges.
- Opportunities include the aging population, globalization, and emerging markets in developing countries.
This presentation is created under a marketing internship.
It is about Virgin group and its various companies and also about Marketing schemes and vulnerability.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Pfizer Inc. is the world's largest pharmaceutical company with global operations in over 79 locations. The company applies science and resources to develop therapies that improve lives. Pfizer divides its business into innovative pharmaceuticals, vaccines and consumer healthcare. Key products include Prevnar/Prevenar 13, Lyrica, and Viagra. While facing competition from generic drugs and facing high barriers to entry, Pfizer maintains a leading market position through a diverse portfolio and strong brand recognition.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of Pfizer's financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
Pfizer is a large pharmaceutical company founded in 1849 and headquartered in New York. It has annual sales of $44.4 billion and focuses on areas like cardiovascular, infectious diseases, and oncology. While Pfizer has significant market share and resources, it also faces threats such as expiring patents, increased competition from generics, and a reliance on blockbuster drugs.
Pharmaceutical industry pestel analysisRahul Pagaria
The pharmaceutical industry in India is a rapidly growing sector that produces low-cost, high-quality drugs. It has a total market size of over $20 billion and has grown at around 12.5% annually over the past five years. Key players in the industry include Ranbaxy, Dr. Reddy's, Cipla, and Lupin. A PESTEL analysis identified political issues like price controls, social factors like an aging population and increased patient expectations, economic challenges from the global crisis, opportunities from new technologies, and an increasing focus on the environmental impact of the industry.
Strategic Management project on Johnson & Johnson Shobhita Dayal
This presentation talks about the complete framework of the strategic planning of the Johnson & Johnson company. All the topics of strategic management course is been covered, in this ppt starting from SWOT, Strategic Map, External Factor Analysis, and all other major strategic tools.
This document provides a business report on Pfizer Inc. prepared by Aileen Marshall. It includes an executive summary analyzing Pfizer's position in the pharmaceutical market. It then gives a company snapshot of Pfizer, including key facts, products, acquisitions and financial performance. Finally, it begins an analysis of Pfizer's current position using a PEST analysis and SWOT analysis to examine political, economic, social, technical, strengths, weaknesses, opportunities and threats facing the company.
Competitive advantage and strategy formulation processvitusmaren
This document discusses the competitive advantages and strategy formulation processes of three large pharmaceutical companies: Novartis, Pfizer, and Sanofi-Aventis. It outlines how Novartis was formed through a merger and leads in various therapeutic areas. Pfizer invests heavily in research and develops blockbuster drugs. Sanofi-Aventis has a large diversified drug portfolio and global vaccine leadership. The strategy formulation process for Novartis is also summarized, including its mission to discover and market innovative products, objectives like eliminating diseases, and potential strategies like investing in R&D.
The document discusses how various factors in the PESTEL analysis impact the pharmaceutical industry in India. It outlines how the political, economic, sociological, technological, ecological, and legal environments can positively or negatively influence the industry. A stable government, growing economy, educated society, advancing technology, balanced environment, and supportive laws create opportunities for pharmaceutical companies to develop and thrive.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
Abbott Laboratories (Pakistan) is a pharmaceutical company founded in 1888 that has been operating in Pakistan since 1948. It has over 1,500 employees and manufacturing facilities in Karachi. The company produces pharmaceuticals, nutritional products, diagnostics, and medical devices. Abbott's main competitors in Pakistan include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, and Pfizer. An analysis of Abbott's strengths, weaknesses, opportunities, and threats was conducted, as well as financial analysis showing steady growth from 2012-2017. Recommendations included focusing on products with fewer side effects, reducing employee turnover, engaging with the government, and adopting new technologies.
Johnson & Johnson is a global healthcare company headquartered in New Jersey. It has over 110,000 employees worldwide and sells products in over 175 countries. In 2011, it achieved $65 billion in sales. The company focuses on consumer health, pharmaceuticals, and medical devices/diagnostics. It aims to provide high-quality products and services to improve health and quality of life. Johnson & Johnson faces competition from companies like Abbott Laboratories, Merck, Novartis, and Pfizer but maintains strength through its diverse product portfolio and strong brand loyalty.
Pfizer is the world's largest pharmaceutical company with revenues of $49.6 billion in 2014. It has over 78,000 employees worldwide and key products include Lipitor, Lyrica, Viagra, and Celebrex. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. Pfizer utilizes a complex global supply chain network involving over 300 suppliers to procure and deliver materials and finished products to customers in over 175 distribution centers worldwide while managing risks such as cargo theft and counterfeiting.
This document provides an analysis of Johnson & Johnson, a global healthcare company. It begins with an overview of the company's history and operations, including its founding in 1886 and presence in over 60 countries. It then analyzes Johnson & Johnson's business segments, competitors, mergers and acquisitions, sales, value chain, and SWOT profile. The document also performs a PEST analysis and recommends how Johnson & Johnson can improve its response to quality control issues to restore its reputation. In summary, the document analyzes Johnson & Johnson's global business environment through an examination of its operations, strategy, and external factors.
Peloton Interactive Analysis by Berkley McFarlinBerkleyMcFarlin
This document provides a comprehensive analysis of Peloton Interactive, Inc. It begins with a financial analysis noting Peloton's high revenues compared to competitors but consistent net losses. An external analysis uses Porter's Five Forces model to examine Peloton's competitive environment and identifies opportunities and threats. An internal analysis evaluates Peloton's value chain and strengths and weaknesses. The document concludes with recommendations for Peloton to respond to COVID-19, optimize competitive opportunities, and increase its stock price.
- The document analyzes the five forces model, PESTLE analysis, and SWOT analysis for a pharmaceutical company.
- It identifies strong competition from generic drugs, high R&D costs, and stringent FDA regulations as challenges.
- Opportunities include the aging population, globalization, and emerging markets in developing countries.
This presentation is created under a marketing internship.
It is about Virgin group and its various companies and also about Marketing schemes and vulnerability.
Branson should apply the following criteria when deciding on new diversifications:
- It should add value to end users and communities in line with Virgin's brand of value, quality, fun and innovation.
- It should benefit from Virgin's resources like its strong brand, management expertise, and ability to innovate in constrained industries.
- The diversification should create opportunities for synergies across Virgin's existing operations through shared resources and capabilities.
Merck & Co. Inc. uses an information system called Merlin to manage customer relationship data from IMS and support decision making across various departments. Merlin collects third party data costing $20 million annually, loads it into an Oracle database, and generates reports using a MicroStrategy support tool. Key data includes hospital performance, market activity, and sales plan information. The system is used by executives, supply chain, accounting, marketing, and sales management to aid pricing, inventory, and strategic advantage decisions.
This document provides an overview of Merck and its recalled drug Vioxx. It discusses Merck's history, leadership, stakeholders, vision, relationship with the FDA, political contributions, use of the blockbuster drug model, direct-to-consumer advertising, Vioxx's rise to fame, emerging safety concerns, and ultimate recall from the market in 2004. The recall came after studies showed Vioxx significantly increased heart attack risks. Questions remain about whether further action should have been taken against those responsible for the deaths and damages caused to consumers by Vioxx.
Merck is facing losing patents on some major drugs like Vasotac and Mevacor. Possible solutions are mergers or focusing on innovation. Merck's new product process was previously slow to respond to competitors, but it now develops cross-functional teams early in the process. Developing specialized patented drugs helps Merck capture new markets. However, drug development faces risks if products fail trials or competitors launch first. The pharmaceutical industry faces challenges like patent expirations and increasing drug resistance. Porter's five forces analysis shows barriers to entry are high in pharmaceuticals due to R&D costs and required scale, while buyers have significant bargaining power.
Merck is a global research-driven pharmaceutical company founded in Germany in 1668 and established in the US in 1891. It is committed to helping patients access medicines for chronic conditions through programs that provide free medicines and prescription discounts. Merck contributes to relief efforts such as donating medicines after disasters. It develops drugs through processes of discovery, testing, clinical trials, and regulatory approval. While the pharmaceutical industry faces risks such as lawsuits and loss of patents, Merck diversifies and innovates its portfolio. It competes with large pharmaceutical companies through strategies like job cuts following its merger with Schering-Plough and developing biotech medications.
This document provides an overview of Merck, a global healthcare company. It discusses Merck's mission to save and improve lives through innovative pharmaceutical products and services. It outlines Merck's history and values, which include a commitment to ethics, access to medicines, and diversity. The document also discusses Merck's leadership, compliance programs, and views on issues like healthcare reform, innovation, and expanding global access to medicines and vaccines.
Comment se construit le storytelling ? Comment fonctionne-t-il ? pourquoi est-il si efficace ? Comment l'utiliser pour vous, votre marque, votre entreprise ? Quelques chiffres et exemples.
Merck & Co. is a pharmaceutical company with a history dating back to 1827. In the 1980s, Merck's performance began to lag behind competitors due to disappointing new products, inflation, and currency exchange rates. Merck's performance appraisal system rated employees on a scale of 1 to 5, but outstanding performers felt they were not adequately rewarded. The system lacked clarity and managers avoided low ratings, fearing employee discontent. In response, Merck formed an Employee Relations Review Committee to examine policies and ensure fair application, consistent communication, and a system encouraging productivity and excellence.
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...Shirshanka Das
Just when you think you have your Kafka and Hadoop clusters set up and humming and you’re well on your path to democratizing data, you realize that you now have a very different set of challenges to solve. You want to provide unfettered access to data to your data scientists, but at the same time, you need to preserve the privacy of your members, who have entrusted you with their data.
Shirshanka Das and Tushar Shanbhag outline the path LinkedIn has taken to protect member privacy in its scalable distributed data ecosystem built around Kafka and Hadoop.
They also discuss three foundational building blocks for scalable data management that can meet data compliance regulations: a centralized metadata system, a standardized data lifecycle management platform, and a unified data access layer. Some of these systems are open source and can be of use to companies that are in a similar situation. Along the way, they also look to the future—specifically, to the General Data Protection Regulation, which comes into effect in 2018—and outline LinkedIn’s plans for addressing those requirements.
But technology is just part of the solution. Shirshanka and Tushar also share the culture and process change they’ve seen happen at the company and the lessons they’ve learned about sustainable process and governance.
Rem de sivir - a classic analysis of desperate measures during desperate timesDr Siddharth Dutta
1. The document analyzes the rise in demand for the drug remdesivir as a COVID-19 treatment. It suggests the demand was driven more by public perception, preferences of pharmaceutical companies, and promotion rather than scientific data.
2. Key events that promoted remdesivir usage included its emergency use authorization in the US and a statement by Dr. Fauci promoting it. This led to a surge in orders and deals by pharmaceutical companies to distribute it globally despite limited evidence of its effectiveness.
3. Questions are raised about whether remdesivir's efficacy was proven given conflicting trial results, the high price paid for it, and whether remaining stocks will be used after shortages were reported in Europe.
The document discusses the growth of the global generics market from 1998-2008. It notes that major pharmaceutical companies are increasingly entering the generics market as the patents on many brand-name drugs expire. This has led to consolidation in the generics industry as large companies acquire smaller generics producers. The generics market is also shifting production to countries like India and Southeast Asia to take advantage of lower manufacturing costs.
The document discusses the growth of the global generics market from 1998-2008. It notes that major pharmaceutical companies are increasingly entering the generics market as the patents on many brand-name drugs expire. This has led to consolidation in the generics industry as large companies acquire smaller generics producers. The generics market is also shifting production to countries like India and Southeast Asia to take advantage of lower manufacturing costs.
Pfizer is facing significant challenges as many of its blockbuster drug patents expire in the coming years. This will open the door for cheaper generic competition that will eat into Pfizer's revenues. As CEO, I would [1] focus R&D on developing new blockbuster drugs to replace revenue losses, [2] look for strategic acquisitions of companies with promising drug pipelines, and [3] strengthen Pfizer's portfolio of treatments for chronic diseases to take advantage of demographic trends. With successful execution of these strategies, Pfizer could remain the world's most valued pharmaceutical company.
The global nutraceutical market is expected to grow from $345 billion in 2011 to approximately $450 billion by 2015, representing an annual growth rate of 7%. Nutraceutical beverages are a key growth area, expected to grow 9% annually through 2015. Nutraceuticals include dietary supplements, functional foods and beverages. While traditionally consumed in pill form, consumers are seeking alternative formats like beverages, foods and shots due to pill fatigue. Innovation in convenient single-serve packaging is driving growth in certain segments. Regulations may impact the industry by reducing the number of products and companies, potentially slowing equipment sales initially as companies adjust.
Managers in the pharmaceutical industry face both opportunities and threats due to a dynamic environment. Demand for pharmaceuticals has grown steadily for decades due to demographics and successful new drugs can be highly profitable. However, developing new drugs takes 10-15 years and costs $800 million on average, with many failing. Additionally, incumbent firms face challenges such as upcoming patent expirations, potential price controls, and reduced prices negotiated by large health providers.
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working together—on the science, the research and the policies—we
can help ensure that medicines live up to patients’ hope for new solutions to our greatest health care challenges.
This document discusses the concept of "megafunds" to help fund research and development for rare diseases. It notes that current sources of funding like venture capital and philanthropic venture capital are not enough to develop treatments for the over 7,000 known rare diseases. It proposes creating large pooled investment funds or "megafunds" that would attract funding from institutional investors by issuing bonds or debt backed by the intellectual property of a portfolio of drug development programs. This could open access to a larger pool of capital to fund more rare disease research more efficiently and at a reduced risk level through diversification. It provides examples of past proposals and discussions around this concept as a potential new model to help bridge the "valley of death"
The History of the FDA and Why It Was Created.pdfFDA Specialist
The Food and Drug Administration (FDA) stands as an essential institution in our modern world, ensuring the safety and efficacy of products that impact our daily lives. This comprehensive regulatory agency has a rich history that dates back to the early 20th century, driven by the urgent need to address rampant issues in the quality and transparency of consumer goods.
In an era when there were virtually no regulations governing the production and distribution of food, drugs, and other commodities, consumers were left vulnerable to a wide range of hazards. Adulterated and misbranded products flooded the market, causing harm, and deception to unsuspecting individuals. The lack of oversight raised public concerns and led to a demand for change.
The turning point arrived with the Pure Food and Drug Act of 1906. This landmark legislation, spurred by increasing public outrage, laid the foundation for federal oversight of product safety. It marked the government's first tangible step toward preventing the sale of unsafe and deceptive goods. The Act aimed to ensure transparency in labeling, ingredient disclosure, and general product quality, setting the stage for a more regulated marketplace.
The evolution continued as the Food and Drug Administration underwent reorganization in 1930. Originally known as the Food, Drug, and Insecticide Administration, the agency expanded its responsibilities and oversight, leading to its renaming as the FDA. This transformation reflected the recognition of the intricate connections between product safety and public health, extending beyond pharmaceuticals and food to include medical devices, cosmetics, and tobacco products.
One of the most pivotal moments in FDA's history occurred during the 1960s with the Thalidomide tragedy. The widespread use of this drug to alleviate morning sickness in pregnant women resulted in severe birth defects, revealing a glaring gap in drug safety regulations. This catastrophe catalyzed the passing of the Kefauver-Harris Amendments in 1962, which mandated not only the safety but also the efficacy of drugs before market approval. This paradigm shift signified a commitment to safeguarding public health, emphasizing that new medications must not only be safe but also provide the intended benefits.
The scope of the FDA's responsibilities has continued to expand over the years. It has played an integral role in responding to various crises, such as the HIV/AIDS epidemic in the 1980s and the ongoing challenges posed by the opioid crisis and the COVID-19 pandemic. These events have underscored the agency's adaptability and unwavering dedication to safeguarding public well-being.
In the ever-evolving landscape of science and technology, the FDA continues to modernize its regulatory processes. It employs risk-based approaches to efficiently allocate resources, ensuring the timely approval of innovative products without compromising safety... For more information visit our website
Johnson & Johnson is a large healthcare company with a history of 10% annual earnings growth. To maintain growth, the company must create $4 billion in new business each year. William Weldon leads efforts to foster collaboration between business units and drive innovation through combining drugs, devices, and diagnostics. However, maintaining growth is challenging as some major drugs face competition and acquisitions are difficult to integrate. Weldon works to improve cooperation and create breakthrough innovations to sustain the company's success.
The document discusses various topics related to wellness during the COVID-19 pandemic. It promotes regenerative agriculture practices that improve soil health and food resilience. It provides information on organizations working on agroforestry and permaculture in Guatemala and East Africa. The document also discusses early treatment protocols for COVID-19 that include vitamins, minerals, and repurposed drugs. It notes the importance of lifestyle factors like nutrition, exercise, stress reduction, and time in nature for wellness.
This document summarizes information about the top 15 pharmaceutical companies in the world in 2015. It provides sales figures and rankings for the top 5 selling drugs worldwide from 2014. It also discusses how the "patent cliff" has affected drug makers as major drugs lose patent protection. Additionally, it outlines key factors for the US pharmaceutical industry's success and discusses the growing pharmaceutical industry and market in India.
This document summarizes a report on the global zoonotic disease treatment market. Zoonotic diseases are those spread between animals and humans. The market is driven by factors like population growth, urbanization, and increased consumption of animal proteins. However, lack of disease awareness, high research costs, and drug prices restrain the market. The market is expected to grow due to rising meat consumption and income levels in developing nations. North America currently dominates the market but Asia Pacific is expected to experience increased zoonotic disease prevalence due to poor sanitation. The report provides an overview, key drivers and restraints, regional analysis, and profiles major market players.
The global market for IV bags has graduated as a key segment within the field of parental packaging and is defined by the supply of plastic materials required in intravenous therapy with key applications in hospital care.
Drop in electrolyte levels is not common among patients suffering from fever and diarrhea. This also causes moderate to severe cases of dehydration, which is more common in children. IV bags are often recommended to administer intravenous therapy for the treatment of such patients.
IV bags have also shown effectiveness in precisely delivery medication directly to veins via blood transfusion. The soaring usability of IV bags in the healthcare sector is indicative of a promising future ahead for the market. On these lines, Transparency Market Research (TMR) has predicted the market for IV bags to surge at a CAGR of 5.8% between 2020 and 2032.
This document provides an overview of a panel discussion on innovative financing trends for European biotechs. The panel will discuss whether EU investors will increase their appetite for risk capital, alternative fundraising options for European companies to achieve more reasonable valuations, and if European companies should seek investment from US markets instead. While European biotech research is strong, US capital markets continue to offer European companies higher valuations, larger investments, and more liquidity compared to domestic exchanges. The panel aims to explore solutions to these regional challenges facing European drug innovators.
The document discusses challenges facing the traditional drug discovery model and opportunities for a new model. The traditional model of big pharma downsizing R&D and biotechs being dependent on venture capital is seen as inefficient. Academia also lacks funding for translational research. However, times may be changing as large pharma forms more collaborations and invests in innovative models like Redx Pharma, which uses science, expertise, and non-dilutive funding to build an early pipeline of assets for partners and achieve sustainability. Quotes from Keynes, Hayek, and an Lilly executive provide perspectives on economic theories and the need for industry evolution to improve patient access.
Johnson & Johnson is a global healthcare company founded in 1886. It operates through three segments: consumer health, pharmaceutical, and medical devices. The company has a presence in over 57 countries and sells products in more than 175 countries. Johnson & Johnson has a diversified product portfolio including brands such as Tylenol, Neutrogena, Band-Aid, and Listerine. The company employs around 114,000 people worldwide.
The pharmaceutical industry faced a challenging period from 2008-2012 due to numerous major drug patents expiring, resulting in $30 billion in lost annual brand drug revenue. Another peak of patent expirations is projected for 2014-2015, equal to the prior period. Growth in overall drug spending declined 1% in 2012 but is predicted to rebound to 3-4% growth in 2014, driven by new drug approvals and healthcare reform, before slowing again as generics continue to capture a larger share of prescriptions. Demonstrating the value of new drugs through real-world evidence will be important for companies to sustain pricing levels in this challenging environment.
GetPersonalized! Pharma's perspective on the future, Claudia KarnbachSitra / Hyvinvointi
Pharma's perspective on the future, Claudia Karnbach, Head, Global Business Development and Licensing, Specialty Medicine, Bayer Healthcare Pharmaceuticals (USA, New York)
3. Industry Background
S ~ $1 Trillion Industry made up of
of the big 12 pharmaceuticals
S High cost of drugs $1.5 Billion
S Time consuming
S Increasingly shorter patents
S Competitive market
S Similar drug developed
S Drive cost of marketing also cost cut strategy
S Others have diversified their portfolio to remain competitive
4. Pfizer
S Oldest pharmaceutical company out of the 12 big corporate giants
S Mamas work force
S 35,000 sales representatives make average of $621,032
S 15,000 scientists and R&D personals.
S R&D and manufacturing facilities on almost every content
S Diverse products and services
S Pharmaceuticals such as Vigra, Lipitor and the up and coming Eliquis
(apixaban)
S Health care products such as Advil, Centromere and chap stick
S Health care insurance (small and local).
S World leading in veterinary medicine
5. Pfizer
S Second biggest market capital of $190 Billion
S Strong and transparent media and social media presences
S Continues updated media release on their website
S Facebook presence
S Twitter
S Youtube
S TV presence
S Total of 2 million followers
S Strong government relationship
7. The Competition
S 12 major pharmaceuticals world wide including Pfizer.
S Either European or American based
S Stronger internet presence
S Diversification of product
and services
8. End of an Era
S Block buster drugs are less desirable
S Budget and personal cuts
S R&D budgets cut by up 3 billion dollars per year
S Reduction in sales representatives
S Pfizer by 3000
S GlaxoSMithKline 4000
S Patent expiry generic drugs
S 42% of drugs off patent by 2013
9. The problem
S Competitors with similar drugs
S Small market space
S Product orientated (Pharmaceuticals and health care
products).
S Have segmented the market but not yet implemented any
market or corporate strategies
S Lack of diversification
10. Medical instrument
S Move into preventative medicine
S Compete and or collaborate in production of medical
instrument
S Use their resources to remain market orientated
S Anticipate competitors next move
11. Health insurance
S Goloblise Health Care insurance
S Use their strong brand value
S Maintain customer relationship
S Use their media and social media presence
S Show the end users that they care not only about how
they are treated by what they eat (Preventative
measures).
12. Orphan Drugs
S To treat a minority group 200,000 people
S Highly risky, but not many companies want to venture
there
S High return
S Anti lung caner drug at $115,210 per patient per year
13. GM Food
S Opportunity for diversification of product and services
S Currently a Niche market
S Not too many competitors
S Potential to expand
S High profit margins
14. GM Food
S World wide shortage of food by 2030
S Less regulation surrounding it
S Can rely on trade secrets than patents
S Faster turn over of product, BUT
S Not widely understood
S Organic produce are still very popular
15. References
S Johnson and Johnson 2012, Johnson and Johnson medical products and technologies, accessed on October 20th, http://www.jnj.com/connect/healthcare-products/medical-technologies/
S Johnson, N 2012, 'Branded Pharmaceuticals Major Manufactures', Henry Fund Research, The University of IOWA, School of Management.
S Johnson Rockoff 2011, The Wall Street Journal, Pfizer's FutureL A Niche Blockbuster, accessed on October 27th http://online.wsj.com/article/SB10001424053111903352704576538683370950462.html
S Herper, M 2012, Forbes Magazine, The best drug Companies of The Past 15 Years, accessed on October 1st http://www.forbes.com/sites/matthewherper/2012/02/09/the-best-drug-companies-of-the-past-15-
years/
S Herper, M 2012, New York Times, Pfizer Inc., accessed on September 20th http://topics.nytimes.com/top/news/business/companies/pfizer_inc/index.html
S Herper, M 2012, Forbes Magazine, Experimental drug business, accessed on http://www.forbes.com/2006/11/27/pfizer-experimental-drugs-biz-cz_mh_1127pfizer.html
S Market Watch 2012, Pfizer Inc., accessed on October 26th http://www.marketwatch.com/investing/stock/pfe
S Pfizer Inc. 2012, Pfizer History 1849-1899, accessed on August 18th http://www.pfizer.com/about/history/1849_1899.jsp
S Pfizer Inc. 2012, Pfizer History 1900 to 1950, accessed on August 18th http://www.pfizer.com/about/history/1900_1950.jsp
S Pfizer inc 2012, Pfizer History 1900 to 1950, accessed on August 27th http://www.pfizer.com/about/history/1900_1950.jsp
S Pfizer inc 2012, Pfizer History 1951 to 1999, accessed on August 27th http://www.pfizer.com/about/history/1951_1999.jsp
S Pfizer inc 2012, Pfizer about Australia, accessed on August 18th <http://www.pfizer.com.au/sites/au/about_pfizer_Australia/Pages/OurHistory.aspx>
16. References
S Pfizer inc 2012, Pfizer History 2000 to present, accessed on September 3rd http://www.pfizer.com/about/history/2000_present.jsp
S Pfizer inc 2012, Pfizer about, accessed on August 18th http://www.pfizer.com/about/
S Pfizer 2012, Pfizer social media, accessed on October 12th http://www.pfizer.com/news/social_media/social_media.jsp
S Standard & Poor’s, 2011, 'Industry Survey; Healthcare: Pharmaceuticals’.
S Pfizer Inc. 2012, Pfizer product pipeline, accessed on August 18th, http://www.pfizer.com/research/product_pipeline/product_pipeline.jsp
S Pfizer Inc. 2012, 'Pfizer Reports Fourth-Quarter and Full-Year 2011 Results; Updates 2012 Financial Guidance', accessed on October 1st.
S The Official board 2012, Pfizer's Corporate structure, accessed on September 29th, http://www.theofficialboard.com/org-chart/Pfizer
S Roger Bate 2008, The American, Bad Medicine, accessed on October 26th http://www.american.com/archive/2008/may-june-magazine-contents/bad-medicine
S Yahoo Finance 2012, Pfizer Inc., viewed on October 26th <http://au.finance.yahoo.com/q/ks?s=PFE>
The Pharmaceuticals industry in general faces great issues involving drug development. Pfizer like its 11 other competitors are reliant on drug manufacturing of block buster drugs and their massive marketing power. Although entities such as Pfizer are pharmaceutical companies, it is also on of the largest marketing companies in the world with an average of 4 Billion spent annually Each block buster drug cost 1.5 billion to develop from finding (lab findings to animal trials) to post marketing, this is also time consuming as it takes 10-15 years with research it self and all regulation, patent, TGA and FDA approvals to name a few (IP Australia 2012). Also legislation is not in the pharmaceutical industries favor as patent laws only give monopoly on their findings of 10 to maximum of 25 years (IP Australia 2011).Drug development business are constantly in a race to see not who will come up with the new revolutionary drug but who will be the first, for example in 2006 Roche brought out similar drug RHHVF to Lipitor (Cholesterol lowering drug) which could have see the nearly out of patent drug, lose sales (Herper 2006). Similarly Merc tried to do the same with torcetrapid, more a blood pressure lowering drug but did receive a bad review from doctors (Herper 2006). Obviously delivery of the best drug would see the entity that developed it triumph, which Pfizer did and continues to do by not only complaining Lipitor with another drug to perlong Lipitor’s patent but also it continues to make Pfizer 12 billion each year (Herper 2006).
Pfizer was started in 1849 by Charles Pfizer, when he borrowed $2,500 off his father to purchase the Brooklyn factory that was the factor, warehouse and head quarters for the 60 years (Pfizer 2012).The German migrant, patterned with his cousin Erhart Pfizer (chemist) who developed their first pharmaceutical product, almond flavored toffee to treat intestinal infections, and creams to treat soars in 19th century America; which was very helpful for the soldiers during the civil war (Pfizer 2012).Pfizer expanded across America and the world from producing products such as citric acid for Coca Cola, Penicillin and Viga to name a few (Pfizer 2012). Many of the great block buster drugs such as Vigra, Lipitor and the up and coming Eliquis (apixaban) which will stop heart attack and stroke (currently in phase III clinical trials) (Pfizer 2012). Also produce a wide range of health care products, also world leading in veterinary medicine.The success of Pfizer is reliant on their mamas sales representative staff of over 35,000 and 15,000 scientist. Also cost of manufacturing and shipping is reduced thanks to their diver production facilities on almost every continent. Which differentiates them from all the other competitors, simply by the shear number of personals and money invested to fuel such operations (4 billion annually on R&D).
Media release giving update to general public, consumers, investors and health professional, all targeted and designed for each sector. 6 FB pages with average of 20,000 likes dedicated to different section of the company eg veterinary medicine, regions and countries, from New York to Egypt. Similarly their twitter present is strong with over 30,000 follower on their main account. 14 Youtube channels informing again consumers, investors and general public what they do in multiple languages from Portuguese, Belgium to Turkish. On top of that Pfizer makes regular segments on news for health advise, with partnership with government officials to increase their public presences.
Top 5 are in revenue capital are : Johnson & Johnson, Pfizer, Roche, Glaxo Smith Kline and Novartis with an average of 49.872 of revenue production annually per company (Herper 2012). The pharmaceutical industry is a reactive strategy their to serve and treat illness and ailment. Johnson & Johnson compete with Pfizer with block buster drugs but also health care product and medical instrument development. Their customer base are made of pharmacies, hospitals, private practice and vets.
Patents run out too soon for Pharmaceutical companies and cost to return ratio is not always worth it! The market (health care professionals) are moving to more customised treatments and one pill fits all is growing less desirable. Hence why they are decreasing their R&D budget and increasing their social presence to maintain customer linking and being market sensitive. Small companies in India are looking at making Vigra for 500% less the cost Pfizer did (Bate 2008).
Pfizer is well aware of companies such as Johnson & Johnson, and Merc making similar drugs and products who are trying to move on their market space. Hence why Pfizer makes products with less side effect to add value to customer, product and attract and return the end users. Need to diversify product range like Johnson and Johnson who are entering into medical instrument production. Pharmaceutical are not longer as profitable maybe diversify their company into a tangible product and services.
Pfizer wants to remain market orientated, so maybe should move in to preventative medicine and compete or collaborate with the likes of Johnson & Johnson (JnJ 2012). The budget cuts to R&D can be channeled into making these instruments, also recruit market analyst and competitor analyst who can give insight on what maybe the competitors next move.
Role out their Health care insurance globally. Use their strong media and social media presence to promote their new products and services, as well increase awareness of prevention is the best medicine (Pfizer 2012).
By 2030, the world will have wheat shortage as the world population increases, this will mean that, many consumers worldwide will be have an unbalanced nutrition that could cause to disease state (Anderson 2012). There are opportunities to expand product and service by expanding into a niche market that will potentially be the future food source of the world.
Less regulation surrounding GM food, which makes it not as desirable by investors at the moment. Product/crop is produced in matter of month not over a decade (Menz 2012). There are many people who hate GM food, as its not organic, believe they use high levels of pesticides and not health, when it is not the case. Possible media presence and education of the general public can sway or make the public aware of the dilemma the world will face and benefits of using GM food.